scispace - formally typeset
C

Christopher J. Logothetis

Researcher at University of Texas at Austin

Publications -  207
Citations -  21806

Christopher J. Logothetis is an academic researcher from University of Texas at Austin. The author has contributed to research in topics: Prostate cancer & Prostate. The author has an hindex of 63, co-authored 207 publications receiving 19324 citations. Previous affiliations of Christopher J. Logothetis include Baylor College of Medicine & National Institutes of Health.

Papers
More filters
Journal ArticleDOI

The Molecular Taxonomy of Primary Prostate Cancer

Adam Abeshouse, +311 more
- 05 Nov 2015 - 
TL;DR: The Cancer Genome Atlas (TCGA) has been used for a comprehensive molecular analysis of primary prostate carcinomas as discussed by the authors, revealing substantial heterogeneity among primary prostate cancers, evident in the spectrum of molecular abnormalities and its variable clinical course.

The Molecular Taxonomy of Primary Prostate Cancer

Adam Abeshouse, +309 more
TL;DR: A comprehensive molecular analysis of 333 primary prostate carcinomas revealed a molecular taxonomy in which 74% of these tumors fell into one of seven subtypes defined by specific gene fusions (ERG, ETV1/4, and FLI1) or mutations (SPOP, FOXA1, and IDH1).
Journal ArticleDOI

Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer.

Katherine A Hoadley, +738 more
- 05 Apr 2018 - 
TL;DR: Molecular similarities among histologically or anatomically related cancer types provide a basis for focused pan-cancer analyses, such as pan-gastrointestinal, Pan-gynecological, pan-kidney, and pan-squamous cancers, and those related by stemness features, which may inform strategies for future therapeutic development.
Journal Article

Expression of the Protooncogene bcl-2 in the Prostate and Its Association with Emergence of Androgen-independent Prostate Cancer

TL;DR: It is indicated that bcl-2 expression is augmented following androgen ablation and is correlated with the progression of prostate cancer from androgen dependence to androgen independence.